Zunhua People's Hospital

Objective To investigate the clin. efficacy of nasal feeding of Huoxue Huayu Decoction, i.v. drip of Xingnaojing Injection, enema with Tongfu Xiere Decoction combined with Western medicine in the treatment of acute severe craniocerebral injury. Methods A total of 80 patients with acute severe craniocerebral injury admitted to the Zunhua People's Hospital from March 2017 to June 2019 were selected and divided into the observation group and the control group according to the random number table method, 40 cases in each group. Both groups were treated with conventional Western medicine, including i.v. drip of Mannitol Injection, Aminotoluene Acid Injection and Edaravone Injection, on this basis, the patients in the observation group were treated with nasal feeding of Huoxue Huayu Decoction, i.v. drip of Xingnaojing Injection and enema with Tongfu Xiere Decoction. Both groups were continuously treated for 18 d. Results During the treatment, the incidence of cerebral vasospasm and cerebral infarction in the observation group was significantly lower than that in the control group(P < 0. 05). After treatment, the Glasgow Coma Scale( GCS) score, activities of daily living(ADL)score and the level of superoxide dismutase(SOD)in the observation group were significantly higher than those in the control group(P < 0. 05), and the blood flow velocity of anterior cerebral artery, middle cerebral artery, posterior cerebral artery and vertebral artery, as well as the levels of malondialdehyde( MDA) and endostatin-1( ET-1) in the observation group were significantly lower than those in the control group(P < 0. 05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group(15. 00% vs. 7. 50%, P > 0. 05). Conclusion The above scheme of integrated traditional Chinese and Western medicine in the treatment of acute severe craniocerebral injury can further improve the coma state, prognosis and quality of life, and reduce the incidence of cerebral vasospasm and cerebral infarction. Its mechanism may be related to improving intracranial blood flow velocity and reducing the oxidative stress response.

Objective To investigate the effect of carvedilol on cardiac function and myocardial injury in non-myocardial infarction patients with coronary heart disease and angina pectoris. Methods A total of 120 non-myocardial infarction patients with coronary heart disease and angina pectoris admitted to the Zunhua People's Hospital from Jan. 2014 to May 2017 were selected and divided into the study group and the control group according to the random number table method, 60 cases in each group. The patients in the two groups were treated with conventional drugs, on this basis, the patients in the study group were treated with Carvedilol Tablets. Both groups were continuously treated for three months. Results In the study group, one case voluntarily dropped out and two cases were lost to follow-up. In the control group, one case was lost to follow-up and one case was missing clin. evaluation data. The clin. data of the above patients were excluded. The total effective rate of the study group was 91. 23%, which was significantly higher than77. 59% of the control group(P < 0. 05). After treatment, the frequency of angina pectoris, numeric rating scales( NRS) score, QT interval dispersion(QTd), levels of cardiac troponin T( cTnT), creatine kinase-MB( CK-MB) and myeloperoxidase( MPO) in the study group were significantly lower than those in the control group, the left ventricular end-systolic diameter( LVESd) and left ventricular end-diastolic diameter(LVEDd)in the study group were significantly shorter than those in the control group, and the 6-min walking distance(6 MWD)in the study group was significantly longer than that in the control group, and the left ventricular ejection fraction(LVEF)in the study group was significantly higher than that in the control group(P < 0. 05). During the treatment, the incidence of adverse reactions in the study group was similar to that in the control group(15. 79% vs. 10. 34%, P > 0. 05). Conclusion On the basis of conventional drug therapy, carvedilol has a certain effect in the treatment of non-myocardial infarction patients with coronary heart disease and angina pectoris, which can reduce the frequency and pain degree of angina pectoris, improve the cardiac function, myocardial injury index and prognosis.

Objective To investigate the clin. efficacy of oxiracetam combined with brain protein hydrolyzate in the treatment of patients with carotid atherosclerotic plaque after cerebral stroke and its effect on cognitive dysfunction and hemorheol. Methods Totally94 patients with carotid atherosclerotic plaque after cerebral stroke admitted to our hospital from Feb. 2017 to Feb. 2019 were selected and randomly divided into the observation group and the control group,47 cases in each group. The patients in the two groups were given anticoagulation,thrombolysis,antiplatelet,blood lipid regulation and other basic treatment,and they were treated with brain protein hydrolyzate,on this basis,the patients in the observation group were treated with Oxiracetam Injection. Both groups were continuously treated for 4 wk. Results The total effective rate of the observation group was 89. 36%,which was significantly higher than72. 34% of the control group( P < 0. 05). After treatment,the scores of Mini-Mental State Examination( MMSE),Montreal Cognitive Assessment Scale( MoCA) and activities of daily living scale( ADL) in the observation group were significantly higher than those in the control group( P < 0. 05),while the levels of high shear whole blood viscosity( HBV),medium shear whole blood viscosity( MBV),low shear whole blood viscosity( LBV),matrix metalloproteinase-9( MMP-9),myeloperoxidase( MPO) and neuron-specific enolase( NSE) in the observation group were significantly lower than those in the control group( P < 0. 05). The incidence of adverse reactions in the observation group was similar to that in the control group( 14. 89% vs. 8. 51%,P > 0. 05). Conclusion Oxiracetam combined with brain protein hydrolyzate in the treatment of cerebral stroke patients with carotid atherosclerotic plaque can significantly improve cognitive function,hemorheol. indexes and serum inflammatory indexes.